US PHARMACOPEIA

Lobbying client · Maryland · filed 2026 to 2026

Pharmaceutical manufacturing

$60,000 Reported spend

4 Filings counted

1 Outside firm hired

3 Bills named

Spend is reported income plus in-house expenses across 4 filings. Everything on this page comes from one LDA client record (72654), filed by the registrant listed below.

Who filed for this client 1

KYLE HOUSE GROUP $60,000 Outside firm · 4 filings

Spend per registrant: fees an outside firm reported, or the costs the client reported for lobbying in-house. The rows add up to the total above.

Bills named in these filings 3

H.R. 8595
National Security, Department of State, and Related Programs Appropriations Act, 2027

2 filings
H.R. 6500
Continuing Appropriations and Extensions Act, 2027

1 filing
H.R. 9770
Continuing Appropriations Act, 2027

1 filing

Reported by year 1 year

2026 $60,000 4 filings

Issues lobbied 2

Foreign Relations 4
Health Issues 4

The count is how many filings named that issue area. A filing reports one lump figure covering every issue on it, so the money above cannot be split between them.

Agencies and chambers lobbied 3

HOUSE OF REPRESENTATIVES 3
SENATE 3
State, Dept of (DOS) 3

Recent filings 4 total

Q3 report

KYLE HOUSE GROUP

3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $20,000 income · posted Oct 20, 2026

View → Q2 report

KYLE HOUSE GROUP

2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $20,000 income · posted Jul 20, 2026

View → Q1 report

KYLE HOUSE GROUP

1st Quarter 2026 (Jan 1 - Mar 31) · House · Senate · $20,000 income · posted Apr 20, 2026

View → Registration

KYLE HOUSE GROUP

1st Quarter 2026 (Jan 1 - Mar 31) · posted Apr 20, 2026

View →

Keep going

Filings through October 20, 2026, the newest posted date on this record. Source: federal Lobbying Disclosure Act filings, synced daily. Money is self-reported by the filer and often rounded. Lobbying is legal, disclosed activity.